During a gluten free diet EMA and AGA disappear. Their presence or absence is therefore an indicator of dietary compliance. After reintroduction of gluten into the diet 110/134 (82%) of the patients who had a flat mucosa at diagnosis relapsed, but 24/134 still had a normal mucosa after 2-15 years of challenge. AU these patients without a morphological relapse were less than 2 years old at diagnosis so we conclude that patients who are young at diagnosis should be challenged. AGA often reappear earlier than EMA. After one month of challenge 93% of patients are AGA and 69% EMA positive. After more than three years of gluten intake the percentage of AGA positive patients decreased to about 50% whereas the percentage of EMA positive sera was then highest (93%). Therefore EMA are more sensitive for the detection of 'silent' relapse after prolonged periods of gluten intake.
Abstract
The value of IgG and IgA gliadin antibodies (AGA) was compared with that of IgA endomysium antibodies (EMA) for the diagnosis of coeliac disease. Three hundred and six of 340 (90%) children with untreated coeliac disease (flat mucosa) had EMA and 338/340 (9944%) had IgG AGA and/or IgA AGA. Only 1/340 (a 7 year old boy with selective IgA deficiency) had neither AGA nor EMA. Absence of EMA is more frequent in coeliac patients younger than 2 years than in older patients (32/277 compared with 1/62). EMA were present in 4/211 (2%) of comparison subjects (normal mucosa), IgA AGA in 12/211 (6%), and IgG AGA in 74/211 (35%). The specificity of AGA cannot be calculated from these figures as they are biased. The combined determination of AGA and EMA, taking advantage of the high sensitivity of AGA and the high specificity of EMA, gives an excellent prediction of the condition of the mucosa: 247/248 patients (99-6%) with positive EMA and positive IgG AGA and IgA AGA had a flat mucosa, whereas 136/137 patients (99.3%) with neither AGA nor EMA had a normal mucosa.
During a gluten free diet EMA and AGA disappear. Their presence or absence is therefore an indicator of dietary compliance. After reintroduction of gluten into the diet 110/134 (82%) of the patients who had a flat mucosa at diagnosis relapsed, but 24/134 still had a normal mucosa after 2-15 years of challenge. AU these patients without a morphological relapse were less than 2 years old at diagnosis so we conclude that patients who are young at diagnosis should be challenged. AGA often reappear earlier than EMA. After one month of challenge 93% of patients are AGA and 69% EMA positive. After more than three years of gluten intake the percentage of AGA positive patients decreased to about 50% whereas the percentage of EMA positive sera was then highest (93%). Therefore EMA are more sensitive for the detection of 'silent' relapse after prolonged periods of gluten intake.
It is well known that the formation of small amounts of antibodies to ingested proteins is a normal physiological occurrence. Low concentrations of antibodies to proteins in nutrients can therefore be demonstrated in nearly all subjects if the test method used is sensitive enough. This is also true for antibodies against gliadin (AGA) .
In [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In 1983 Chorzelski et al described IgG antibodies against endomysium (EMA) and found a close correlation between these antibodies and patients with dermatitis herpetiformis. Later they also found EMA in patients with coeliac disease.20 21 EMA are directed against extracellular reticular fibres in the endomysium that surrounds the smooth muscle cells of many species.
Our aim was to compared the diagnostic significance of IgG AGA and IgA AGA with that of IgA EMA for coeliac disease in children.
Patients and methods

PATIENTS
We studied 551 patients who had undergone a first jejunal biopsy because of suspected coeliac disease from children's hospitals throughout Switzerland and Germany. Their ages ranged from 4 Sensitivity and specificity Sensitivity is defined as the percentage of positive results in patients with the disease in question. Specificity is defined as the percentage of negative results in patients not suffering from the disease in question. In the case of AGA, estimates of sensitivity and specificity are biased by the fact that only a small proportion of the patients with negative AGA tests underwent biopsy.
Most sera sent to our laboratory have negative results for AGA. On the other hand a positive test for AGA was regarded as an indication for biopsy. The prevalence of false positive cases shown in table 1 was therefore higher than in the original population. In order to compensate for this bias a method proposed by Begg and Greenes was used. 22 No such direct connection between the test result and the decision to perform a biopsy exists for EMA. Neither in children with a flat mucosa nor in those with a normal mucosa could a significant association between the tests for AGA and EMA be demonstrated (X2 test in 2x2 tables). Estimates of sensitivity and specificity can therefore be calculated from the present data without gross systematic errors. From a theoretical standpoint a planned experiment for the determination of sensitivity and specificity would be desirable. In order to obtain substantially more accurate estimates than in the present study, several hundred subjects with a flat mucosa as well as with a normal mucosa would be necessary. On ethical grounds such a procedure cannot be advocated.
Predictive values
The positive predictive value of a test is defined as the proportion of true positives in the total number of positives, and the negative predictive value of a test is defined as the proportion of true negatives in the total number of negatives. Both predictive values are related to the prevalence of the disease in the population studied and therefore are not characteristic constants of the test procedure. In the present data the positive predictive value of the case where all three antibody tests were positive was estimated as Absence of IgA EMA is more frequent in patients younger than 2 years than in older subjects (32/277 compared with 1/62, the patient with IgA deficiency is omitted from the statistical analysis). This difference is significant: p= 0-0082, Fisher's one tailed exact test in 2x2 tables.
We found EMA in only 4/211 disease controls (table 2) . Altogether 207/211 (98%) of the Figure 1 shows the percentages of sera that are still positive in 86 patients (table 4) . The children with relapse were initially diagnosed at an age between 5 months and 10-9 years (median 1-3 years). All children without relapse were younger than two years at diagnosis (6 months-1-7 years, median: 10 months).
The age at challenge varied widely from just under 3 to 18 years in patients both with and 181-360 * 361-720 * >720 Days of gluten free diet Figure Frequency ofIgA AGA, IgG AGA, and EMA after introduction ofa glutenfree diet (157 sera from 86 children; number of sera in each group is shown).
without relapse. The final morphological outcome therefore does not seem to be influenced by the age at challenge.
Persistent gluten intolerance was definitively demonstrated in 110 patients who had been biopsied at diagnosis. Some of them had to be biopsied two or even three times during challenge before the relapse became morphologically manifest, which results in 125 biopsies being carried out in 110 patients. Twelve (28%) of 43 patients who-were biopsied after one month of challenge still had a normal mucosa. If the biopsy was postponed until between two months and one year of gliadin loading, only 2/ 33 (6%) did not yet show a morphological relapse (their challenge period was seven or 10 months), and only 1/19 (5%) if it was postponed from one to two years (challenge period 20 months). All biopsies done after at least two years of challenge were pathological.
(b) Antibodies during challenge AGA titres after challenge in patients with relapse were often not as high as the original titres in untreated coeliac disease. In about 50% of sera only IgG AGA were found and in a few cases only IgA AGA. We therefore can discuss only AGA irrespective of the isotypes found. Before challenge the percentage of antibody positive patients (fig 2) was low (AGA 23%, EMA 13%) but not zero; this is a reflection of dietary non-compliance. AGA are generally produced shortly after the beginning of the challenge, as shown in fig 2. Fifty (93%) of 54 patients with antibody tests produced AGA after 14 to 35 days. The percentage of sera with AGA is highest (97%) after a challenge period of about four weeks to three months and decreases thereafter to only 49% after three or more years of gliadin intake. As regards individual patients, some of them showed the following antibody time course. The AGA increased in an initial phase but later declined again and in some patients even became negative, although the biopsy specimen showed a severely damaged mucosa at the end of the challenge. This increase and decrease of AGA in individual patients explains the diminishing percentages of patients positive for AGA during long challenge periods (fig 2) . EMA are produced later in the challenge than AGA but they do not disappear after a prolonged challenge (fig 2) . In the first month of challenge only 690/o of patients had EMA. The highest percentage (93%) of patients positive for EMA was reached after three and more years of gliadin intake.
AGA were found in 9/54 patients (16%) without morphological relapse and EMA were present in 6/54 (11%). These antibody positive patients were challenged for between three months and four years. Some of them, espe- Figure 2 AGA and EMA before and during challenge with gluten in patients with relapse (390 serafrom 135 children; percentage ofpositive sera in each group is shown; number of positive sera/total number tested is shown below figure) . As a consequence of many studies-'9 it has recently become the custom of many paediatric gastroenterologists not to take biopsy specimens from patients when no antibody can be found29 unless a strong clinical suspicion of coeliac disease is contradictory to the serological result. A positive antibody result, however, is taken as an indication for biopsy. The question arises of whether it would not also be possible to refrain from carrying out a biopsy in children younger than 2 years if the three antibody tests (IgG AGA, IgA AGA, EMA) are positive. In this age group the number of children without relapse on challenge is very high, 11-18% in our study, even if these patients presented a flat mucosa at initial biopsy. A challenge after remission is therefore required in all cases if the children are less than 2 years old at diagnosis. In conclusion, nearly all patients with persistent gluten intolerance produce antibodies at some time, but they show a wide individual variation as regards time and the type (AGA, EMA) and quantitites of the antibodies they produce. The pathophysiological role of AGA and EMA is still unknown. As we showed recently,33 EMA is probably identical with an antijejunal antibody directed against collagen fibres in human jejunum. We consider this antibody to be an autoantibody of coeliac disease.
Uniparental disomy and genomic impnting Sex is dead. Oh, really? Yes, well it must be because, according to a distinguished group of geneticists,' it has left a legacy-the fact that chromosomes and genes come in pairs. Be that as it may, the phenomenon of genomic imprinting (see Archivist 1991:80) is a fascinating one which seems as yet to have no very satisfactory explanation. The most commonly quoted clinical example of this phenomenon is, of course, the fact that Angelman's syndrome and the Prader-Willi syndrome appear to result from a deletion in the same region of the long arm of chromosome 15 (15q 11-13) and the deletion is always of maternally derived material in Angelman's syndrome and of paternally derived in the Prader-Willi syndrome.
It was reported in 1989 that the Prader-Wilhi syndrome could result from uniparental maternal disomy-that is, both chromosomes coming from the mother.2 Now two of a total of 76 patients with Angelman's syndrome have been shown to be disomic for the paternal chromosome 15.1 As the patients are in all respects similar to others with this syndrome it seems unlikely that the absence of other maternally derived genes on this chromosome has any appreciable deleterious effect. Thus imprinting is clinically relevant in probably only a small proportion of the genome. It is not yet established that the responsible gene is the same in the two syndromes but if not identical they are very close or overlapping.
From the point of view of genetic counselling the finding is of some significance. When parental chromosomes are normal the risk of recurrence is low for Prader-Willi syndrome but higher (more than 8%) for Angelman's syndrome. If parental disomy can be demonstrated, however, that indicates a very low risk in either syndrome. 
